FEIBA [Anti-Inhibitor Coagulant Complex] Dosing

Taking FEIBA

Infusing, at home and on your own.

Loren, Actual FEIBA Patient

Once you and your doctor determine your dose and you receive training, you can infuse at home with a few steps. Create a comfortable routine and get ready to infuse.

FIND the right dose.

  • FEIBA comes in 3 dosage strengths: 500 units, 1000 units, and 2500 units.1
  • Color-coded boxes and vial labels make it easy to identify each dose level.
  • Work with your doctor to decide which strength is right for you.

Store at room temperature.

  • Choose a cabinet, closet, drawer, or cupboard that keeps FEIBA away from direct sunlight and extreme hot or cold.
  • Storage conditions should not exceed 77°F (25°C).
  • Store FEIBA in its original package to protect it from light.
  • Avoid freezing. It could damage the diluent vial.1

PREP in just 3 steps.

FEIBA comes packaged with the BAXJECT II Hi-Flow Needleless Transfer Device. Mixing with the BAXJECT II Hi-Flow device requires fewer steps than the previous BAXJECT device, and it's color-coded for more intuitive reconstitution (also known as "mixing").1,14


Connect the diluent vial.


Connect the FEIBA vial.


Withdraw mixed FEIBA.

BAXJECT II Hi-Flow Product Information
Rx only
. For safe and proper use of this device, please refer to the Instructions for Use in the FEIBA full Prescribing Information.

NOTE: The BAXJECT II Hi-Flow device should be used only with FEIBA. The BAXJECT II Hi-Flow device is intended for use with a single vial of product and is for single use only. Therefore, reconstitution and withdrawing a second vial into the syringe requires a second BAXJECT II Hi-Flow device.

Get the step-by-step details.

See how to mix and prep FEIBA.

Find troubleshooting tips.

FEIBA contains no preservatives. Aseptic technique should be used throughout the entire reconstitution process and the solution should then be used immediately.

Download instructions and tips


It's important to remain still while you're infusing. Relax with music and soft lighting or find an activity that can help you stay calm. Read, watch a movie, or call Grandma Betty. She always loves to hear from you.

Want to learn more? Check out our Tools & Resources section.


FEIBA [Anti-Inhibitor Coagulant Complex]
Indications and Detailed Important Risk Information for Patients

Indications for FEIBA

FEIBA is an Anti-Inhibitor Coagulant Complex approved for use in hemophilia A and B patients with inhibitors for:

  • Control and prevention of bleeding episodes
  • Use around the time of surgery
  • Routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

FEIBA is NOT for use in the treatment of bleeding episodes resulting from coagulation factor deficiencies without inhibitors to factor VIII or factor IX.

Detailed Important Risk Information for FEIBA


  • Blood clots that block blood vessels and their effects have been reported during post-marketing surveillance following infusion of FEIBA, particularly following administration of high doses (above 200 units per kg per day) and/or in patients at risk for forming blood clots.
  • If you experience any of these side effects, call your doctor right away.

Who should not use FEIBA?

You should not use FEIBA if:

  • You had a previous severe allergic reaction to the product
  • You have Disseminated Intravascular Coagulation (DIC), or signs of small blood vessel clots throughout the body
  • You have sudden blood vessel clots or blocked blood vessels, (such as, heart attack or stroke)

What other important information should I know about FEIBA?

Events involving blood clots blocking blood vessels (such as blood clot in vein, blood clot in the lung, heart attack, and stroke) can occur with FEIBA, particularly after receiving high doses (above 200 units per kg per day) and/or in patients with risk factors for clotting.

Events of thrombotic microangiopathy (TMA), a condition where blood clots and damage occur in small blood vessels, were reported in an emicizumab (Hemlibra®) clinical trial where patients received FEIBA with emicizumab as part of a treatment plan for breakthrough bleeding. The safety and efficacy of FEIBA for breakthrough bleeding in patients receiving emicizumab has not been established. If you take, or anticipate taking, FEIBA with emicizumab, tell your doctor, since they will need to closely monitor you.

At first sign or symptom of a sudden blood vessel clot or blocked blood vessel (such as chest pain or pressure, shortness of breath, fever, altered consciousness, vision, or speech, limb or abdomen swelling and/or pain), stop FEIBA administration right away and seek immediate emergency medical treatment.

Infusion of FEIBA should not exceed a single dose of 100 units per kg body weight and daily doses of 200 units per kg of body weight. Maximum injection or infusion rate must not exceed 2 units per kg of body weight per minute.

Allergic reactions, including severe, sometimes fatal allergic reactions that can involve the whole body, can occur following the infusion of FEIBA. Stop using FEIBA promptly and call your doctor or get emergency treatment right away if you get a rash, hives or welts, experience itching, tightness of the throat, vomiting, abdominal pain, chest pain or tightness, difficulty breathing, lightheadedness, dizziness, nausea or fainting.

Because FEIBA is made from human plasma it may carry a risk of transmitting infectious agents, such as viruses, variant Creutzfeldt-Jakob disease (vCJD) and, theoretically, the Creutzfeldt-Jakob disease (CJD).

What are the possible side effects of FEIBA?

The most common side effects observed during the prophylaxis clinical study were low number of red blood cells, diarrhea, bleeding into a joint, positive test for hepatitis B surface antibodies, nausea, and vomiting.

The serious side effects seen with FEIBA are allergic reactions and clotting events involving blockage of blood vessels, which include stroke, blockage of the main blood vessel to the lung, and deep vein blood clots.

Call your doctor right away about any side effects that bother you during or after you stop taking FEIBA.

What other medications might interact with FEIBA?

Talk with your doctor about the possibility of formation of blood clots when taking drugs that may prevent clot breakdown such as tranexamic acid, and aminocaproic acid. There have not been adequate studies of the use of FEIBA and rFVIIa (NovoSeven®), or emicizumab together, or one after the other. Use of drugs that may prevent clot breakdown within approximately 6 to 12 hours after the administration of FEIBA is not recommended.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088

Please see FEIBA full Prescribing Information, including BOXED WARNING on blood clots, and discuss with your doctor.